

AWARD NUMBER DAMD17-98-1-8468

TITLE: Combined Use of Tissue Morphology, Neural Network Analysis of  
Chromatin Texture & Clinical Variables to Predict Prostate  
Cancer Agressiveness From Biopsy Mater

PRINCIPAL INVESTIGATOR: Alan W. Partin, M.D., Ph.D.

CONTRACTING ORGANIZATION: The Johns Hopkins University School of Medicine  
Baltimore, Maryland 21205-2196

REPORT DATE: October 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

20010404 129

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

|   |   |  |   |   |                        |
|---|---|--|---|---|------------------------|
| 1. AGENCY USE ONLY (Leave blank)  |   | 2. REPORT DATE<br>October 2000                             |   | 3. REPORT TYPE AND DATES COVERED<br>Annual Summary (1 Oct 99 - 30 Sep 00) |                        |
| 4. TITLE AND SUBTITLE<br>Combined Use of Tissue Morphology, Neural Network Analysis of Chromatin Texture and Clinical Variables to Predict Prostate Cancer Aggressiveness From Biopsy Material  |   |  |   | 5. FUNDING NUMBERS<br>DAMD17-98-1-8648                                    |                        |
| 6. AUTHOR(S)<br>Alan W. Partin, M.D., Ph.D.   |   |  |   |   |                        |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>The Johns Hopkins University School of Medicine<br>Baltimore, Maryland 21205-2196   |   |  |   | 8. PERFORMING ORGANIZATION<br>REPORT NUMBER                               |                        |
| E-MAIL:   |   |  |   |   |                        |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012   |   |  |   | 10. SPONSORING / MONITORING<br>AGENCY REPORT NUMBER                       |                        |
| 11. SUPPLEMENTARY NOTES<br>This report contains colored photos  |   |  |   |   |                        |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for public release; Distribution unlimited   |   |  |   |   | 12b. DISTRIBUTION CODE |
| 13. ABSTRACT (Maximum 200 Words)<br><br><p><b>Purpose:</b> To combine clinical, serum, pathologic and computer derived information into an artificial neural network to develop/validate a model to predict prostate cancer tumor aggressiveness in both a retrospective and prospective cohort of men with clinically localized prostate cancer both prior to and after radical prostatectomy.</p> <p><b>Scope:</b> Prospective enrollment of 500 men who are scheduled to undergo radical retropubic prostatectomy (year 01). Development of an artificial neural network (year 02). Prospective validation of this model (projected year 03). All models will be tested and developed for biopsy and prostatectomy material.</p> <p><b>Major Findings:</b> To date, we have completed prospective enrollment of 557 men, collected tissue, serum and clinical/pathological information for 493 and completed computer image data analysis of 402 samples. We currently have begun construction of a model to predict prostate cancer aggressiveness and anticipate completion of this task by December 2000. At this time, prospective enrollment of a validation subset will begin.</p> |   |  |   |   |                        |
| 14. SUBJECT TERMS<br>Prostate Cancer  |   |  |   | 15. NUMBER OF PAGES<br>19   |                        |
|   |   |  |   | 16. PRICE CODE  |                        |
| 17. SECURITY CLASSIFICATION<br>OF REPORT<br>Unclassified  | 18. SECURITY CLASSIFICATION<br>OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION<br>OF ABSTRACT<br>Unclassified | 20. LIMITATION OF ABSTRACT<br>Unlimited |   |                        |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


\_\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

☒ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature

10/19/95  
Date

JAMES BUCHANAN BRADY UROLOGICAL INSTITUTE

THE JOHNS HOPKINS HOSPITAL  
BALTIMORE - MARYLAND 21287-2101  
(410) 614-4876 / FAX: (410) 614-8096  
Email: apartin@jhmi.edu

ALAN W. PARTIN, M.D., Ph.D.  
BERNARD L. SCHWARTZ  
DISTINGUISHED PROFESSOR  
OF UROLOGIC ONCOLOGY

October 30, 2000

Department of the Army  
US Army Medical Research and Materiel Command  
ATTN.: MCMR-RMI-S  
504 Scott Street  
Fort Detrick, MD 21702-5012


Dear Ms. Judy Pawlus,

Please find enclosed our annual summary for our project entitled *Combined Use of Tissue Morphology, Neural Network Analysis of Chromatin Texture and Clinical Variables to Predict Prostate Cancer Aggressiveness from Biopsy Material*. The summary details a description of the training for the project and a list of research accomplishments to date.

The information contained within this report does not contain any proprietary/or unpublished information. Therefore, no pages are marked for protection.

Please do not hesitate to contact me if you have any questions or concerns regarding any information contained within.

Sincerely,



Leslie Mangold  
Research Program Coordinator/Dr. Alan Partin  
Johns Hopkins University  
Office (410) 955-1504  
E-Mail lmangold@jhmi.edu

Enclosure

## Table of Contents

|                          |        |
|--------------------------|--------|
| Front Cover              | Page 1 |
| Standard Form (SF 298)   | Page 2 |
| Foreword                 | Page 3 |
| Cover Letter             | Page 4 |
| Table of Contents        | Page 5 |
| Introduction             | Page 6 |
| Body: Specific Aims      | Page 6 |
| Research Accomplishments | Page 8 |
| Reportable Outcomes      | Page 8 |

Appendix A: Poster Presentation, AUA 2000

Appendix B: Abstract, AUA 2001

Appendix C: Summary Table

## Introduction:

Several specific objectives were outlined for our research proposal entitled *Combined use of Tissue Morphology, Neural Network Analysis of Chromatin Texture and Clinical variables to Predict Prostate Cancer Aggressiveness from biopsy Material*. We proposed to combine standard prognostic methods (clinical stage, PSA, Gleason score, and biopsy information) with Neural Network analysis of chromatin texture and computer derived tissue morphology prospectively to predict pathologic stage. We also intended to retrospectively investigate in prostatectomy specimens using a similar combination of clinical, histologic and computer derived characteristics to predict disease recurrence following surgery. This resulting technology and nuclear analysis would then be applied to study a group of men with long term follow-up after surgery to develop and validate this technology in predicting recurrence following surgery. Lastly, we intended to use this methodology to develop and validate an accurate model for predicting time to metastatic progression/death after biochemical recurrence. With these specific objectives outlined, a statement of work was submitted detailing the task and time line necessary to accomplish the goals of the proposal. Task one of our statement of work outlined the steps involved in the prospective enrollment of 500 men for prediction of pathologic stage model development. Completion of this objective was projected for 9 months following the initiation of this project. Below are the initial steps outlined in Task one, followed by an update of our progress to date.

## Body: Specific aims

A. Identification and prospective enrollment of consecutive radical prostatectomy cases performed at the Johns Hopkins Hospital.

**557 patients have been enrolled with 409 successfully fulfilling all inclusion criteria.**

**The exclusion of 148 patients was due to: canceled RRP, no response from original biopsy institution, no cancer present in remaining biopsy material.**

B. Obtain tissue blocks for each case.

**Tissue blocks have been obtained for all patients admitted into this research study.**

C. Cut and prepare histologic sections.

**Histologic sections have been obtained from all cases.**

6

D. Measure nuclear features with the QNG model.

**Image analysis has been completed on 402 (98%) cases.**

E. Enter all clinical, pathological, and quantitative nuclear data into the computer.

**Clinical and pathological data for 409 patients has been collected and organized into a relational database.**

F. Multivariate analysis to determine optimal prognosis prediction model.

**DNA ploidy analysis and pathologic review has been completed on 402 cases (98%).  
Model construction has begun and should be complete by December 2000.**

Task two of our approved statement of work details the steps necessary for prospective enrollment of 400 men for pathologic stage model validation. This portion of the project has a projected completion of 13 months following project initiation.

**The initiation of this task has been delayed until model construction and image analysis is completed.**

Task three of the research proposal outlines the steps involved in predicting tumor aggressiveness from biopsy/prostatectomy specimens. This portion of the statement of work should be completed by month 14 of the study. Our progress to date is indicated below:

A. Obtain tissue blocks from 300 cases treated at Johns Hopkins with radical prostatectomy.

**300 pathological specimens have been identified. Collection of these cases has begun and should be complete by January 2001.**

B. Cut histologic sections and prepare slides for QNG analysis.

**This portion of task three will be conducted following completion of section A with an anticipated date of completion of April 2001**

C. QNG determinations

**Refer to task 3, section B comment.**

D. Tissue morphology analysis.

**Refer to task 3, section B comment.**

F. Enter clinical data, pathological information, QNG results and tissue morphology into a database.

**Clinical and pathological data for 300 patients has been collected and organized into a relational database.**

G. Calculate model for prediction of post-operative progression from prostatectomy specimens.

**This step will be completed following collection of all data involved with task three.  
Anticipated completion of this initiative May 2001.**

Task four involves validation analyses from prostatectomy specimens for prediction of tumor aggressiveness. Our initial statement of work projected completion of this portion of the project by month 30 (March 2001). The identification and analysis of these additional 100 prostatectomy specimens will begin immediately following the tumor aggressiveness model construction detailed in task three. We believe that completion of this initiative will be prior to month 30 deadline initially proposed.

Lastly, task five of this research study involves retrospective development of a model for prediction of development of metastasises/death following biochemical recurrence following surgery. This task involves identification of 300 men who have exhibited biochemical or metastatic recurrence following surgery.

A. Obtain tissue blocks from 300 cases treated at Johns Hopkins with radical prostatectomy.  
**Tissue blocks for 304 cases have been collected.**

B. Cut histologic sections and prepare slides for QNG analysis.  
**Histologic sections have been obtained for all cases identified for this task.**

C. QNG determinations  
**Feulgan staining has been completed on 100 (33%) cases. Pathologic review has begun on these cases. QNG analysis will proceed following pathologic review of the stained slides.**

D. Tissue morphology analysis.  
**Tissue morphologic analysis will proceed following pathologic review of the Feulgan stained slides.**

F. Enter clinical data, pathological information, QNG results and tissue morphology into a database.  
**Clinical and pathological data for 304 patients has been collected and organized into a relational database.**

G. Determine the prognostic significance of combined variables to predict 3, 5 and 7 year likelihood of remaining metastases free by developing and validating a model for prediction.  
**This portion of task five will be begin following QNG and morphology analysis completion. We anticipate model completion by January 2001.**

#### Research accomplishments:

- Prospective enrollment of 557 patients.
- Biochemical profile (PSA, FPSA, Complex PSA) complete on 420 patients.
- Biopsy material obtained on 493 patients.
- Histology completed on 409 cases.
- Image analysis completed on 402 cases.

#### Reportable outcomes:

- Manuscript in press. Reference: Steven R. Potter, M. Craig Miller, Leslie A. Mangold, Kerrie A. Jones, Jonathan I. Epstein, Robert W. Veltri, and Alan W. Partin. *Genetically Engineered Neural Networks for Predicting Prostate Cancer Progression after Radical*



*Prostatectomy*, Submitted June 1999.

- Poster presented at the American Urological Association Conference  
Prediction of Pathologic Stage in Clinical Stage T1c Prostate Cancer, Veltri, R.W.,  
Miller, M.C., O'Dowd G.J., Mangold, L.A., Epstein, J.I., Partin, A.W., April 2000.  
(Attached)
- Abstract, Submitted to American Urological Association Conference, April 2001  
Improved Accuracy for Prediction of Organ-Confined Prostate Cancer (Pca) in a  
Contemporary Referral Series: The New Challenge, Veltri, R.W., Miller, M.C., Mangold,  
L.A., Epstein, J.I., Sokol, L.J., and Partin, A.W. (Attached)

**PREDICTION OF PATHOLOGICAL STAGE IN CLINICAL STAGE T1c PROSTATE CANCERS.**

Robert W. Veltri, Michael C. Miller, Gerard J. O'Dowd, Oklahoma City, OK; Leslie A. Mangold, Jonathan I. Epstein, Alan W. Partin, Baltimore, MD.

**INTRODUCTION AND OBJECTIVE:** A new challenge for management of prostate cancer involves the ability to predict pathologic stage in patients with clinical stage T1c disease. We constructed a statistical model to predict the organ confinement status in these patients.

**METHODS:** A total of 101 patients with clinical stage T1c prostate cancer were prospectively evaluated. All patients underwent radical prostatectomy at the Johns Hopkins Hospital, and the pathological staging was performed by a single pathologist (JIE). Twenty-eight percent of these patients had non-organ confined disease. Feulgen stained, 5 micron sections from the positive biopsies of these patients were reviewed and the cancer areas were graded and marked (GJO). Approximately 125 cancer nuclei were captured from the highest Gleason score area of each case utilizing an AutoCyte Pathology Workstation with QUIC-DNA v120l software. The variance of 60 different nuclear size, shape, and chromatin texture features were calculated for each set of nuclei and used to determine a quantitative nuclear grade (QNG) for each case. The QNG, along with the patient age, highest Gleason grade (4/5), and pre-operative PSA were analyzed using logistic regression.

**RESULTS:** Using univariate logistic regression analysis, QNG provided the largest area under the curve (AUC 72%) compared to the other input variables, which ranged from an AUC = 58% - 63%. Applying backwards stepwise logistic regression at a stringency of  $p < 0.05$  resulted in a model containing QNG, Gleason grade 4/5, and PSA with an AUC = 78% for the prediction of the disease organ confinement status. At a cutoff of 0.5, the accuracy of the model was 81%, with a positive predictive value of 74% and a negative predictive value of 83%.

**CONCLUSIONS:** Utilizing a new quantitative image analysis based variable, QNG, in combination with pre-operative biopsy and PSA data, we were able to more accurately predict post-operative stage in clinical stage T1c prostate cancer patients.

**Source of funding:** UroCor, Inc. and Department of Defense Grant #DAMD17-98-1-8468

## INTRODUCTION

Prostate cancer (PCa) is the most common malignancy among men in the United States, affecting over 179,300 men and resulting in about 37,000 deaths in 1999<sup>1</sup>.

Approximately 30% of men who are treated for localized disease will recur, and a subset of these men will progress<sup>2</sup>.

Prior to the commercial availability of the serum prostate specific antigen (PSA) test around 1987, the clinical staging of prostate cancer (PCa) utilized the digital rectal examination (DRE) and the transrectal ultrasound guided biopsy<sup>2-4</sup>.

Most patients diagnosed early with organ-confined tumors are curable about 90-95% of the time with radical prostatectomy<sup>5</sup> or about 85-95% with radiation therapy<sup>6</sup>.

There are a significant number (~60-70%) of patients with clinical stage T1c disease (PSA > 2.5 ng/ml and non-palpable disease) presenting at diagnosis that have advanced pathology (grade and stage) at radical prostatectomy<sup>7-10</sup>.

Studies of various nuclear features, such as nuclear roundness and chromatin complexity, on PCa cells from radical prostatectomy sections demonstrated that nuclear morphometric descriptors (NMDs) from PCa epithelial cells are prognostic<sup>10-11, 14</sup>.

Using computer-assisted image analysis, we applied a proprietary process to create a new pathological biomarker of genetic instability, termed Quantitative Nuclear Grade (QNG<sup>TM</sup>)<sup>10-11, 14-15</sup> (Figure 1).

Using a new quantitative imaging system (Figure 2), we evaluated the use of the QNG<sup>TM</sup> variable in biopsy cases with Clinical Stage T1c to predict pathological stage.

# MATERIALS AND METHODS

## PATIENT SAMPLE

- From a total of 557 patients enrolled in a 2 ½ year prospective Prostate Cancer study funded by the Department of Defense (Grant # DAMD17-98-1-8468), we selected biopsies from a subset of men with clinical stage T1c disease where we had the following information (*Tables 1A & 1B*):
  - Age at the time of Biopsy
  - Pre-Operative PSA Level
  - Gleason Grades and Score of Biopsy
  - Feulgen Stained 5µ Tissue Section from Prostate Biopsy
  - Pathological Stage
- A total of 101 patients with clinical stage T1c underwent radical prostatectomy surgery at the Johns Hopkins Hospital, and pathological staging was performed by a single pathologist (JIE). Twenty-eight of these patients were determined to have non-organ confined disease (*Table 1A*).

## QUANTITATIVE NUCLEAR GRADE (QNG™) DETERMINATION:

- Feulgen stained, 5µ prostate biopsy tissue sections were reviewed and the cancer areas were graded and marked by a single pathologist (GJO).
- Approximately 125 cancer nuclei were captured from the highest Gleason score area of each case utilizing an AutoCyte Pathology Workstation with QUIC-DNA v1201 software (*Figures 1 & 2*).
- The variance of each of the 60 NMDs (i.e. different nuclear size, shape, DNA content, and chromatin texture features) were calculated for each case (*Figure 1*)<sup>10, 11, 14, 15</sup>.
- Using univariate logistic regression analysis, the p-value and area under the receiver operator characteristics curve (ROC-AUC) for the variance of each NMD was determined (*Table 2*).
- Using backwards stepwise logistic regression at a stringency of  $p < 0.20$ , a multivariate model to calculate the QNG™ value was created, and it utilized 6 of the 17 univariately significant NMDs (*Table 2 & Figure 3*).

## OC VS. NOC PREDICTIVE MODEL CONSTRUCTION:

- Univariate logistic regression analysis was used to determine the ability of the independent variables to predict the pathological stage (binary outcome of Organ confined [OC] vs. Non-organ confined [NOC]). (See *Table 3 & Figure 4*).
- Using the age, total PSA, presence of Gleason grade 4 and/or 5, the Gleason score, and the QNG™ value, a backwards stepwise logistic regression model was constructed with a stringency of  $p < 0.05$ . This multivariate model retained the total PSA, the presence of Gleason grade 4 and/or 5, and the QNG value to predict OC vs. NOC (*Table 3 & Figure 4*).

## SUMMARY

- Clinical Stage T1c offers a new challenge for pre-treatment pathological staging and represents a very significant portion of prostate cancers being diagnosed today.
- Quantitative Nuclear Grade (QNG™) is an image-based morphometric measurement of genetic instability derived using a multivariately significant subset of 60 different NMDs that measure nuclear size, shape, DNA content, and chromatin organization features.
- QNG™, when combined with Gleason Grade 4/5 and total serum PSA information, predicted the pathological stage with an accuracy of 81% and a ROC-AUC of 78%.
- We plan to expand the training set to include additional biomarkers (i.e. molecular forms of PSA) and validate this clinical stage T1c pre-treatment staging algorithm.

## CONCLUSIONS

- Quantitative image analysis offers a new and accurate tool to assess genetic instability cost effectively and reproducibly on both biopsy and radical prostatectomy material.
- In spite of the strong contribution of quantitative morphometry to predict the stage and progression, there remains a need to identify new and effective biomarkers that can aggregately make pre-treatment algorithms more accurate.
- Improved patient staging allows the urologist and patient to make more informed decisions for patient disease management from diagnosis through definitive treatment.

## REFERENCES

1. Landis SH, Murray T, Bolden S, and Wingo PA. Cancer Statistics, 1998. *CA Cancer J.*, 49: 8-31, 1999.
2. Merrill RM, and Brawley OW. Prostate cancer incidence and mortality rates among white and black men. *Epidemiology*, 8: 126-131, 1997.
3. Orozco R, O'Dowd GJ, Kunnel B, Miller MC and Veltri RW. Observations of pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. *Urol.* 51: 186-195, 1998.
4. O'Dowd GJ, Miller MC, Orozco R, and Veltri RW. Analysis of repeat biopsy results within one year following a non-cancer diagnosis. *Urology*, 55: 553-59, 2000.
5. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. *JAMA*, 281: 1591-1597, 1999.
6. Shipley WU, Thames HD, Sandler HM, *et al.* Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. *JAMA*, 281: 1598-1604, 1999.
7. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. *J. Urol.* 158: 687-698, 1997.
8. Ghavamian R, Blute ML, Bergstralh EJ, Slezal J and Zincke H. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. *Urol.* 54: 105-110, 1999.
9. Polascik TJ, Oesterling JE and Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. *J Urol*, 162: 293-306, 1999.
10. Veltri RW, O'Dowd GO, Orozco R, Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the pre-operative prediction of CaP staging and prognosis. *Seminars in Urologic Oncol.* 16: 106-107, 1998.
11. Veltri RW, Miller MC, Partin AW, Coffey DS, and Epstein JI. Ability to predict biochemical progression using Gleason score and computer-generated quantitative nuclear grade derived from cancer cell nuclei. *Urol.* 48: 685-91, 1996.
12. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, *et al.* (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. *JAMA* 277(18): 1445-1451.
13. Bostwick DG and Qian J. Current and proposed biological markers in prostate cancer: 1994. *J. Cell. Biochem. Suppl* Yarbrow JW, Page DL, Fielding LP, Partridge EE, Murphy GP. American Joint Committee on cancer prognostic factors consensus conference. *Cancer* 86: 2436-2446, 1999.
14. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P., O'Dowd GJ, Veltri RW. An algorithm for predicting non-organ confined prostate cancer using the results obtained from sextant core biopsies and prostate specific antigen level. *J. Urol.* 156: 1375-1380, 1996.
15. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, Partin AW. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. *Urol.* 54: 79-85, 1999.

**Table 1A: Patient Sample Description**  
**(n=101 Clinical Stage T1c Prostate Cancers)**

| Pathologic Stage* | N  | Mean Values (Median Values) |               |                |             |
|-------------------|----|-----------------------------|---------------|----------------|-------------|
|                   |    | tPSA (ng/ml)                | Age at Biopsy | Biopsy Gleason | QNG Score   |
| OC                | 73 | 6.1 (5.8)                   | 57 (58)       | 6 (6)          | 0.23 (0.19) |
| NOC-CP            | 25 | 9.0 (6.5)                   | 56 (56)       | 6 (6)          | 0.35 (0.28) |
| NOC-Mets          | 3  | 10.8 (10.6)                 | 56 (57)       | 7 (7)          | 0.71 (0.72) |


\* OC = Organ Confined; NOC-CP = Non-Organ Confined due to Capsular Penetration Only; NOC-Mets = Non-Organ Confined due to Seminal Vesicle and/or Lymph Node Involvement

**Table 1B:**


| Gleason Score | Biopsy   | Radical  |
|---------------|----------|----------|
| $\leq 5$      | 5 ( 5%)  | 6 ( 6%)  |
| 6             | 68 (67%) | 79 (78%) |
| 7             | 28 (28%) | 14 (14%) |
| $\geq 8$      | 0 ( 0%)  | 2 ( 2%)  |

# **Figure 1: Method for QNG™ Determination**

**Analyze Specimen Using Image Analysis System, Generate a DNA Ploidy Histogram, and Save Nuclear Images for the Calculation of the Quantitative Nuclear Grade (QNG)**



**Calculate Size, Shape, and DNA complexity Features for each of the Nuclear Images saved in the Computer Files and Create the Quantitative Nuclear Grade Solution**



**Figure 2: AutoCyte™ Pathology Workstation  
(TriPath Imaging Inc., Burlington, NC)**



- Zeiss Axioskop Microscope
- 3CCD Color Camera
- High Resolution (768x494)
- Square Pixels
- ~60 Nuclear Morphometric Descriptors
- User Friendly Software
- High Speed / High Capacity Computer System
- Commercially Available and not Cost Prohibitive

# Table 2: Logistic Regression Analysis of NMDs

| AutoCyte Morphometry Measurements |                                 | Univariate Analysis   |         |
|-----------------------------------|---------------------------------|-----------------------|---------|
|                                   |                                 | OC vs. NOC Prediction |         |
| Variable                          | Variable Description            | p-value               | ROC-AUC |
| Var1                              | Cell Class                      | 0.0615                | 63.31%  |
| Var2                              | Perimeter                       | 0.0205                | 67.27%  |
| Var3                              | Area                            | 0.0320                | 67.32%  |
| Var4                              | Circular Form Factor            | 0.8890                | 56.36%  |
| Var5                              | Diameter Equivalent Circle*     | 0.0171                | 68.98%  |
| Var6                              | Feret X                         | 0.0707                | 62.33%  |
| Var7                              | Feret Y                         | 0.0148                | 68.93%  |
| Var8                              | Minimum Feret                   | 0.0413                | 66.78%  |
| Var9                              | Maximum Feret                   | 0.0181                | 67.07%  |
| Var10                             | Area Convex Hull                | 0.0327                | 67.12%  |
| Var11                             | Perimeter Convex Hull           | 0.0187                | 68.00%  |
| Var12                             | Excess of Gray Values           | 0.4589                | 55.33%  |
| Var13                             | Skewness of Gray Values         | 0.2702                | 55.68%  |
| Var14                             | StdDev of Gray Values           | 0.2623                | 57.63%  |
| Var15                             | Mean Gray Value                 | 0.0361                | 62.57%  |
| Var16                             | Median Gray Value               | 0.0405                | 61.59%  |
| Var17                             | Maximum Gray Value              | 0.1345                | 57.34%  |
| Var18                             | Minimum Gray Value              | 0.2503                | 59.44%  |
| Var19                             | Intensity                       | 0.0516                | 65.70%  |
| Var20                             | Integrated OD                   | 0.0176                | 65.66%  |
| Var21                             | Minimum OD                      | 0.1199                | 57.73%  |
| Var22                             | Maximum OD                      | 0.4021                | 48.53%  |
| Var23                             | Median OD                       | 0.1808                | 57.29%  |
| Var24                             | Mean OD                         | 0.1488                | 57.68%  |
| Var25                             | StdDev OD                       | 0.3431                | 53.96%  |
| Var26                             | Skewness of OD                  | 0.4047                | 52.35%  |
| Var27                             | Excess of OD                    | 0.5609                | 48.04%  |
| Var28                             | DNA Ploidy                      | 0.0465                | 67.07%  |
| Var29                             | DNA Index                       | 0.1294                | 67.86%  |
| Var30                             | Transmission                    | 0.0387                | 62.43%  |
| Var31                             | Variance                        | 0.9709                | 52.25%  |
| Var32                             | Sum Mean                        | 0.9392                | 49.85%  |
| Var33                             | Sum Entropy-AC                  | 0.2730                | 63.26%  |
| Var34                             | Sum Variance-AC                 | 0.1345                | 61.99%  |
| Var35                             | Cluster Shade                   | 0.0654                | 62.18%  |
| Var36                             | Cluster Prominence              | 0.0517                | 62.43%  |
| Var37                             | Diagonal Moment                 | 0.0759                | 59.20%  |
| Var38                             | Kappa                           | 0.1015                | 58.17%  |
| Var39                             | Sum of Homogeneity              | 0.0533                | 60.23%  |
| Var40                             | Angular Second Moment           | 0.0159                | 65.90%  |
| Var41                             | Contrast                        | 0.2442                | 56.70%  |
| Var42                             | Correlation                     | 0.5103                | 54.31%  |
| Var43                             | Difference Moment               | 0.2831                | 55.38%  |
| Var44                             | Inverse Difference Moment       | 0.0694                | 59.78%  |
| Var45                             | Sum Average                     | 0.8554                | 50.20%  |
| Var46                             | Sum Variance-M                  | 0.4997                | 55.58%  |
| Var47                             | Sum Entropy-M                   | 0.2721                | 59.05%  |
| Var48                             | Entropy                         | 0.0470                | 61.59%  |
| Var49                             | Difference Variance             | 0.3128                | 55.43%  |
| Var50                             | Difference Entropy              | 0.1220                | 58.32%  |
| Var51                             | Information Measure A           | 0.1433                | 57.68%  |
| Var52                             | Information Measure B           | 0.3701                | 61.15%  |
| Var53                             | Maximal Correlation Coefficient | 0.6748                | 51.91%  |
| Var54                             | Coefficient of Variation        | 0.0299                | 62.33%  |
| Var55                             | Peak Transition Probability     | 0.2280                | 64.73%  |
| Var56                             | Diagonal Variance               | 0.0159                | 65.90%  |
| Var57                             | Diagonal Moment                 | 0.1639                | 60.13%  |
| Var58                             | Second Diagonal Moment          | 0.7463                | 53.13%  |
| Var59                             | Product Moment                  | 0.9392                | 49.85%  |

Areas shaded in gray indicate univariately significant NMDs.

Areas shaded in yellow indicate univariately significant NMDs that were retained in the multivariate QNG model.

T1c QNG Model Predictive Index ( $X_b$ ) Formula (Fig. 3):

$$X_b = -6.037824 + (\text{Var5})(24.53941) + (\text{Var9})(4.157673) + (\text{Var10})(-0.0388227) + (\text{Var11})(-2.127776) + (\text{Var20})(0.001242) + (\text{Var54})(5605.381)$$

$$\text{QNG Value } (P_x) = e^{X_b} / (1 + e^{X_b})$$



**Table 3: Logistic Regression Analysis Results for OC vs. NOC Disease (n=101 Clinical Stage T1c PCa)**

| Independent Variable            | p-value  | ROC-AUC |
|---------------------------------|----------|---------|
| Age at Biopsy                   | 0.2501   | 57.53%  |
| Pre-Operative Total PSA (ng/ml) | 0.0041   | 61.11%  |
| Presence of Gleason Grade 4/5   | 0.0113   | 62.94%  |
| Gleason Score                   | 0.0166   | 62.99%  |
| QNG <sup>TM</sup>               | 0.0001   | 72.31%  |
| tPSA, Gleason Grade 4/5, QNG*   | < 0.0001 | 77.94%  |

\*Pred Index ( $Xb$ ) =  $-3.905151 + \text{tPSA} \times (0.1287485) + \text{Gleason Grade 4/5} \times (1.220584) + \text{QNG} \times (5.423082)$  See  
*Figure 3 for Logistic Regression Formulas*

### **Figure 3: Logistic Regression Formulas**

$$\text{Predicted Index } (Xb) = b_0 + b_1x_1 + \dots + b_nx_n$$

$$\text{Pred. Probability } (P_x) = e^{Xb} / (1 + e^{Xb})$$

**Where:**

$b_0$  = Logistic regression intercept term (model constant).

$b_1 - b_n$  = Weighting characteristic for variables  $x_1 - x_n$ .

$x_1 - x_n$  = Independent variables used in logistic regression model.

$e$  = natural log function

**IMPROVED ACCURACY FOR PREDICTION OF ORGAN-CONFINED PROSTATE CANCER (PCa) IN A CONTEMPORARY REFERRAL SERIES: THE NEW CHALLENGE** Veltri RW, Miller, MC, Mangold LA, Epstein JI, Sokol LJ, and Partin, AW (Presentation by Dr. Partin)

**INTRODUCTION:** The choice of definitive therapy for men with localized PCa is often based upon *their* likelihood of having organ-confined (OC) disease. This decision is currently derived from limited pre-treatment clinical and laboratory information. Nomograms such as the "Partin Tables" offer clinically useful population statistics to guide this decision process, however, do not provide patient-specific results. The changing demographics of PCa in contemporary series (e.g. PSA, Gleason Score and Clinical Stage) are unable to accurately predict pathological stage patients at this critical decision step in disease management. This study utilizes a unique combination of existing and investigational biomarkers to address this contemporary challenge in patients with T1c disease.

**METHODS:** We prospectively enrolled 557 men between 10/98 and 01/00 scheduled for radical prostatectomy at a single institution and 386 (69%) were diagnosed with T1c disease. Exclusion criteria included neoadjuvant treatment or medications, which could effect serologic or histologic presentation of PCa. Pre-operative sera, biopsy histology slides, clinical demographic information, prostatectomy pathology and gland weight were obtained. Biomarkers assessed included: total PSA (tPSA), complexed PSA (cPSA), freePSA (fPSA), f/tPSA ratio, Quantitative nuclear grade (QNG), cPSA-density, and biopsy Gleason score. Logistic regression was used to determine the most accurate combination of variables for predicting OC disease. A cross-validation method of data analysis was performed.

**RESULTS:** Complete data were available for 254/386 (66%) men with T1c disease (average age, 58.8 +/- 6 years). A total of 49/254 (19%) had pathologically non-organ-confined disease. Univariate analysis of the pre-treatment variables showed that QNG, biopsy Gleason score, tPSA, calculated f/tPSA ratio, cPSA, and cPSA density were significant. Using backward stepwise logistic regression at a stringency of  $p < 0.10$ , only QNG, cPSA-density, and Gleason score remained in the model and yielded an area under the ROC curve of 81.6%. The sensitivity and specificity of the model at a cutoff of 0.14 was 75.5% and 73.2% respectively with a negative predictive value of 92.6%.

**CONCLUSION:** These data demonstrate accurate pre-treatment prediction of OC disease in a contemporary series of men with T1c PCa based upon only use of QNG, cPSA-density and biopsy Gleason score.

# DOD Study Task 1 Summary (10/25/2000)

- Total # Patients Enrolled in Study → 557 (100%)
  - # “Completed” Patients → 493 ( 89%)
  - Total # “Completed” Patients Excluded from Study because of No Cancer on Bx or Microwave Processing → 84 ( 17%)
- 
- Total # “Completed”, Non-Excluded Patients (Cases) → 409 ( 83%)
  - # “Completed”, Non-Excluded Cases with Slides where Pathology Review and DNA Ploidy Analysis are Completed → 402 ( 98%)
  - # “Completed”, Non-Excluded Cases with Slides that need second section Feulgen stained and reviewed by Pathology → 7 ( 2%)

**\*Note:** A “Completed” case refers to those where a consent form was received, a response was received from the path institution regarding the biopsy, no pre-op hormones were used, and a radical was performed.